About Globus Medical, Inc. Class A Common Stock (GMED)
Globus Medical Inc is a medical device company that specializes in the development and commercialization of innovative products for spine surgery. The company focuses on creating solutions that enhance surgical outcomes and improve patient recovery through advanced technologies, including surgical implants, instruments, and robotics. With a robust portfolio, Globus Medical aims to address various spinal conditions and assist healthcare professionals in providing effective treatment options, ultimately striving to elevate the standard of care in spine surgery. Read More
AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
What a fantastic six months it’s been for Globus Medical. Shares of the company have skyrocketed 62.5%, hitting $87.15. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 18.7% gain over the past six months, beating the S&P 500 by 7.6 percentage points.
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion.
The best of these businesses balance profitability with reinvestment, setting themselves up for long-term success.
AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-reported basis. Full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5 percent over the prior year on an as-reported basis.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Shares of medical device company Globus Medical (NYSE:GMED)
jumped 2.7% in the afternoon session after several analyst firms raised their price targets, reflecting a positive outlook on the medical technology company's stock.
Shares of medical device company Globus Medical (NYSE:GMED)
jumped 2.6% in the afternoon session after RBC Capital raised its price target on the stock to $100 from $92, while keeping an "Outperform" rating. The new target represented an 8.7% increase. The positive sentiment was also supported by developments in the company's clinical trials.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
